Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx is a buy with a PT of $19 due to their strong financials and potential growth opportunities. Their cash and equivalents at the end of 4Q25 were $265M, and they have a positive outlook for their lead products, Ibsrela and Xphozah, as well as a potential expansion of Ibsrela's label to include chronic idiopathic constipation. The recent Phase 3 trial for Ibsrela in CIC anticipates enrollment completion by YE26, and a potential sNDA filing in 2H27. Overall, Ardelyx is well positioned to capture a significant portion of the market in both the IBS-C and CKD-related hyperphosphatemia spaces, and the potential expansion into CIC provides additional upside to their already strong financials and growth prospects.

Bears say

Ardelyx is expected to face increased operating expenses in FY26 as it invests in its SG&A infrastructure and advances its drug Tenapanor, branded as IBSRELA, in a Phase 3 study for Chronic Idiopathic Constipation (CIC). While the company expects strong revenue growth for both IBSRELA and XPHOZAH, these revenue targets may be challenging to achieve given the limited market potential and competition in the targeted segments. Additionally, the success of the CIC indication and differentiation of IBSRELA will be crucial to driving long-term growth and maintaining investor confidence.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.